|1.||Oku, A: 8 articles (04/2002 - 03/2000)|
|2.||Ueta, K: 7 articles (05/2001 - 03/2000)|
|3.||Saito, A: 7 articles (05/2001 - 03/2000)|
|4.||Arakawa, K: 6 articles (05/2001 - 03/2000)|
|5.||Tsuda, K: 4 articles (04/2002 - 08/2000)|
|6.||Adachi, T: 4 articles (04/2002 - 08/2000)|
|7.||Yasuda, K: 4 articles (04/2002 - 08/2000)|
|8.||Nawano, M: 4 articles (05/2001 - 03/2000)|
|9.||Kano-Ishihara, T: 4 articles (05/2001 - 03/2000)|
|10.||Anai, M: 3 articles (05/2001 - 03/2000)|
04/01/2002 - "Thus, improvement of hyperglycemia by T-1095 ameliorates beta-cell function by relieving [Ca(2+)]i response."
08/01/2000 - "Administration of 0.03% and 0.1% (wt/wt diet) T-1095 to STZ rats for 4 weeks improved the hyperglycemia and dose-dependently decreased HbA1c. "
03/10/2000 - "Continuous administration of T-1095 to diabetic rats for 6 weeks (0.1% in diet) improved not only hyperglycemia, but also the elevation of plasma free fatty acid and plasma ketone body levels. "
03/01/2000 - "In contrast, in skeletal muscles, the reduced GUR was not significantly improved in response to amelioration of hyperglycemia by T-1095 treatment. "
08/01/2000 - "These data suggest that T-1095 improves hyperglycemia by suppressing the renal reabsorption of glucose, which results in a suppression of the development of functional and histological changes and abnormal expression of GLUT2 in the kidney."
|3.||Diabetic Neuropathies (Diabetic Neuropathy)
04/22/2005 - "Treatment of T-1095 significantly prevented the development of diabetic neuropathy in male GK rats. "
04/22/2005 - "Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats."
10/01/2004 - "In addition to this direct blood glucose lowering effect, T-1095 has been shown to restore impaired insulin secretion from pancreatic beta-cells, as well as to improve insulin resistance in muscle and liver. "
11/01/2000 - "We investigated the effects of T-1095 (3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-(6-O-methoxycarbonyl)-beta-D-glucopyranoside), an orally active inhibitor of Na+-glucose cotransporter, on hyperglycemia and insulin resistance in skeletal muscle of streptozotocin (STZ)-induced diabetic rats. "
03/01/2000 - "To determine the contribution of hyperglycemia to the insulin resistance in various insulin-sensitive tissues of Zucker diabetic fatty (ZDF) rats, T-1095, an oral sodium-dependent glucose transporter (SGLT) inhibitor, was administered by being mixed into food. "
12/01/2000 - "In conclusion, T-1095 is the first orally active agent which has an acute antihyperglycemic action in the absence of endogenous insulin secretion with a low risk of hypoglycemia and has therapeutic potential for treatment of diabetes mellitus."
01/01/2006 - "T-1095, an orally active inhibitor of Na(+)-glucose cotransporter (SGLT), excretes excess plasma glucose into urine, lowers blood glucose levels, and thus has therapeutic potential for treatment of diabetes mellitus. "
11/01/2000 - "These data suggest that T-1095 improves insulin sensitivity in skeletal muscle through correction of hyperglycemia and has novel therapeutic potential for treatment of diabetes mellitus through removing glucose toxicity."
|2.||Blood Glucose (Blood Sugar)
|5.||Facilitative Glucose Transport Proteins (Glucose Transporter)